AbbVie Inc.

174.95
0.75 (0.43%)
At close: Apr 11, 2025, 3:59 PM
175.61
0.38%
After-hours: Apr 11, 2025, 05:58 PM EDT
0.43%
Bid 175.35
Market Cap 309.48B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) 2.39
PE Ratio (ttm) 73.2
Forward PE 14.41
Analyst Buy
Ask 175.89
Volume 6,832,470
Avg. Volume (20D) 7,262,466
Open 173.81
Previous Close 174.20
Day's Range 169.33 - 176.97
52-Week Range 153.58 - 218.66
Beta 0.54

About ABBV

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (...

Sector Healthcare
IPO Date Jan 2, 2013
Employees 55,000
Stock Exchange NYSE
Ticker Symbol ABBV
Full Company Profile

Analyst Forecast

According to 20 analyst ratings, the average rating for ABBV stock is "Buy." The 12-month stock price forecast is $214, which is an increase of 22.32% from the latest price.

Stock Forecasts

Next Earnings Release

AbbVie Inc. is scheduled to release its earnings on Apr 25, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+3.39%
AbbVie shares are trading higher after multiple fi... Unlock content with Pro Subscription
2 months ago
+4.7%
AbbVie shares are trading higher following better-than-expected Q4 financial results.